[ad_1]
Eli Lilly Very popular Weight loss pills Reduces risk of type 2 diabetes in obese or overweight adults by 94% Prediabetes Compared with placebo, Preliminary results That’s from a long-term study released Tuesday.
The company is in late-stage trials for tirzepatide, the active ingredient in its weight-loss injection. Zeppelin The study of the diabetes drug Mounjaro also found that patients continued to lose weight over the roughly three-year treatment period. Adults taking the highest weekly dose of the drug lost an average of 22.9% of their body weight after 176 weeks, compared with a 2.1% loss for those taking a placebo.
Shares of the pharmaceutical giant rose nearly 3% on Tuesday.
The findings suggest that Lilly’s treatment can significantly delay the diagnosis of people with prediabetes, or those whose blood sugar levels are higher than normal but not high enough to be classified as type 2 diabetes.
More than one third More Americans are suffering from prediabetes than ever before, according to new government data, health experts say Can be reversed by changing your lifestyle Such as diet and exercise. People who are overweight or obese Higher risk of prediabetes.
New data also suggest there may be long-term health benefits from taking a popular class of obesity and diabetes drugs called GLP-1s, which mimic hormones produced by the gut to suppress appetite and regulate blood sugar. Eli Lilly’s Zepbound and Mounjaro, as well as rival injectables Novo Nordisk In the past two years, these companies have been racing to research Other clinical uses Their medications.
The results are “another reminder that Lilly has invested a lot of money to show that this drug not only produces weight loss, but that it translates into health benefits. This is the fourth study this year where we’ve achieved results like this,” Eli Lilly CEO David Ricks told CNBC, adding that in three other clinical trials, tirzepatide has shown potential to treat heart failure, sleep apnea and fatty liver disease.
Eli Lilly tested tirzepatide in more than 1,000 adults in a phase 3 trial for 176 weeks, after which patients stopped treatment at a 17-week interval. According to the company, this is the longest study of the drug ever completed.
The drugmaker will submit the latest results to a peer-reviewed journal and Upcoming Medical Conferences November. Eli Lilly released 72 Week Weight Loss Results In 2022, researchers studied a larger group of patients in the same trial, called SUMOUNT-1.
During the trial, patients who stopped taking tirzepatide began to regain weight and their chances of developing diabetes increased, but according to the latest phase 3 results, these patients still had an 88% lower risk of developing diabetes compared with those taking a placebo.
“We can maintain a healthy weight for three years on this drug and prevent diabetes,” Ricks told CNBC. “When you stop taking the drug, a subset of people do start to gain weight and then … start to develop diabetes again.”
However, Ricks noted that patients “don’t recover completely, just like they never took the drug.”
Eli Lilly said the safety data of tirzepatide during the trial was consistent with previous studies of the drug. The most common side effects were gastrointestinal reactions, such as diarrhea, nausea, constipation and vomiting, which were generally mild to moderate in severity.
Eli Lilly’s Zepbound works by mimicking two naturally occurring gut hormones, GLP-1 and GIP.
GLP helps reduce food intake and appetite. GIP also suppresses appetite and can improve the way the body breaks down sugars and fats.
[ad_2]
Source link
